CC312 clinical trials
CC312 is named as an intervention in 4 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Early Phase 1. The lead sponsor is CytoCares Inc. The most-studied condition is SLE - Systemic Lupus Erythematosus.
Patient leaflets for CC312
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of CC312
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
NCT06037018 · ClinicalTrials.gov ↗ · Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
|
Phase 1 | Recruiting | CytoCares Inc | China |
|
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
NCT07177911 · ClinicalTrials.gov ↗ · SLE - Systemic Lupus Erythematosus
|
Phase 1 | Recruiting | CytoCares Inc | China |
|
Safety Study of CC312 in Autoimmune Disease Patients
NCT06888960 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc)
|
Early Phase 1 | Recruiting | CytoCares Inc | China |
|
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
NCT07193810 · ClinicalTrials.gov ↗ · SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies, SSc-Systemic Sclerosis
|
Early Phase 1 | Recruiting | CytoCares Inc | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with CC312
10 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| CytoCares Inc | 4 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 4 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about CC312 trials
How many clinical trials are testing CC312?
4 current trials in our China register name CC312 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are CC312 trials recruiting patients?
Yes. 4 of the 4 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors CC312 clinical trials?
The lead sponsor is CytoCares Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how CC312 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CC312 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CC312 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.